Hepatitis C may not be on your radar as a drug plan sponsor. But with the benefits—and costs—of new therapies, it will be.
Globally, there are 200 million people infected with hepatitis C.
There’s a high burden of illness in developing countries such as Africa due to “medical misadventure” such as using unsterilized needles, explained Dr. Jordan Feld, hepatologist, assistant professor, Toronto Western Hospital Liver Clinic, at a recent AbbVie Canada event on drug plan sustainability.
Labels: Why you should care about hep C